Currently operating in more than 150 countries with around 100,000 employees, Pfizer is committed to providing the medical world with innovative products developed to contribute to human health and quality of life. Pfizer cooperates with non-governmental organizations, universities and governments to improve society’s access to effective health solutions and innovative treatments all over the world.
Founded in the USA in 1849, Pfizer achieved its milestones with the mass production of Penicillin, referred to as the miraculous medicine of the world, in 1942, and its international expansion to the world by founding its first businesses in countries such as the UK, Cuba, Mexico and India in 1951. Having served society by presenting, up to the 2000s, many products which are leaders in different therapeutic fields, Pfizer undertook its first merger by acquiring Warner Lambert in 2000, becoming the world’s fastest-growing pharmaceutical company. In 2003, Pfizer incorporated Pharmacia, and assumed the title of the world’s largest pharmaceutical company based on R&D after this merger. Finally, Pfizer incorporated Wyeth, the world’s leading pharmaceutical company, and Ferrosan, one of Denmark’s oldest firms, in 2009 and 2011 respectively. With these mergers, Pfizer has increased and diversified its product portfolio and also strengthened its facilities in the areas of biotechnology, vaccines, health products, nutrition and animal health, which has positioned Pfizer as the world’s leading biopharmaceutical company.
As the pharmaceutical company that has made the largest investment in R&D with 87 production centers worldwide, Pfizer increased its annual R&D resources to USD 7 billion. Pfizer still carries out 78 projects from discovery stage to licensing stage in eight research centers across the world, as well as 250 R&D cooperation throughout the world.
Pfizer started its operations in Turkey in 1957. Having served Turkish medicine and society for over half a century, Pfizer Turkey produces 72 percent of the products in Turkey with its more than 1,000 employees and exports 4.5 percent of these. Pfizer Turkey exports its production to a total of 22 countries in Central and Eastern Europe, including EU countries, the Middle East and the Far East.
Pfizer Turkey is referred to as “A School of Leaders”, since it continuously transfers its successful executives to Pfizer companies worldwide. Today, more than 35 Turkish senior executives are appointed to Pfizer affiliates all around the world.
Currently, Pfizer is conducting a total of 37 international R&D projects in Turkey. Paving the way for developing pharmaceuticals in Turkey for the purpose of improving the country’s R&D environment, Pfizer has completed many important projects since 2009. The “Key Strategic Center” agreement that initiated the strategic cooperation process for pharmaceutical R&D with Hacettepe University is one of the firsts in this area in Turkey. Within the scope of this cooperation, the company signed a memorandum of understanding with the Republic of Turkey Prime Ministry Investment Support and Promotion Agency of Turkey (ISPAT) in order to deepen the quality and quantity of R&D activities in Turkey and develop an environment that will support innovations in the area of pharmaceuticals, and subsequently opened the Pfizer R&D office in Hacettepe Technopolis. In 2010, various programs for fostering pharmaceutical R&D were planned and carried out by a steering committee of 10 executive members from Hacettepe University, Pfizer’s Global Pharmaceutical Research and Development Department and Pfizer Turkey authorities. Following this meeting, concrete steps were taken towards bringing together researchers from Hacettepe University with Pfizer’s global R&D network. Five projects were awarded in May 2011 in the field of “Pfizer Health Sciences and Technologies” in Hacettepe Technopolis Innovation Project Competition, thus creating projects which produce industrial products and technology for Turkey and world, and contribute to the universal science, technology and humanity was aimed.
Regarding the strategic cooperation for pharmaceutical R&D with Hacettepe University, Pfizer’s CEO said, “The agreement we signed is of great importance for both bringing in the accomplishments of the Turkish scientists to the global pharmaceutical R&D network and increasing R&D activities and innovations in the area of pharmaceuticals by providing added value to the Turkish economy. In order to find new treatments that patients need and contribute to economic development, we are looking forward to seeing the projects of Turkish scientists.”
In November 2012, Pfizer launched its third facility in Turkey after the USA and Ireland for the production of Pneumococcal Conjugate Vaccine, one of the most significant biotechnological products in the world. The vaccine, which is also included in the National Vaccine Calendar of the Turkish Ministry of Health, is referred to as the first vaccine produced in Turkey with state-of-the-art technologies starting from the formulation stage. While Turkey has become a self-sufficient country in terms of pneumococcal vaccine with this investment, a total of 21 million dosages of vaccine will be supplied to the Ministry of Health to be used at Health Centers and Centers for Maternal and Infant Health in three years. Crucial stages such as required investments for installation and equipment, personnel trainings, trial productions within the scope of the project have been completed and production of first validation series commenced in April-May 2012, while the required stability studies were concluded successfully. The licensing process for the domestic production of the previously imported vaccine was also completed and the first locally produced vaccines were released as of 2012.
Having invested over TRY 8 million in education and health-oriented social responsibility projects over the last decade, Pfizer Turkey continues to meet the needs and contribute to the welfare of Turkish society.
Working for “A Healthier Life”, as it has done for 55 years, Pfizer Turkey is determined to continue investing in Turkey and being a significant contributor in the Turkish healthcare system.